Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention.
Hepatocyte growth factor (HGF), otherwise known as scatter factor (SF), has been demonstrated over the past decade to elicit a number of functions that may be tumorigenic, and enhance the invasive/metastatic nature of cancer cells. Clinical studies have also demonstrated that HGF/SF, together with its receptor, cMET, is closely related to the disease progression and prognosis of patients with cancer. The past few years have seen the identification of numerous inhibitors and antagonists to the action of HGF/SF. These factors have demonstrated a possible role in minimising the action of HGF/SF on cancer cells, and may be of therapeutic value in the future. This article overviews the activators, inhibitors, and antagonists to HGF/SF and discusses the possible implications in cancer therapy.
Parr
C
C
University Department of Surgery, University of Wales College of Medicine, Heath Park, Cardiff, UK. parrc@cf.ac.uk
Jiang
W G
WG
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001711:Biotransformation / Q000187:drug effects; D017228:Hepatocyte Growth Factor / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012697:Serine Endopeptidases / Q000302:isolation & purification / Q000494:pharmacology* / Q000502:physiology
D000970:Antineoplastic Agents; D017228:Hepatocyte Growth Factor; C081092:HGF activator; D012697:Serine Endopeptidases